Role of monoclonal antibodies in tumor-specific immunity

Expert Opinion on Biological Therapy

Volumn 7, Issue 3, 2007, Pages 331-343

  Nicodemus, Christopher F ^a   Smith, L Mary ^a   Schultes, Birgit C ^a  

^a Unither Pharmaceuticals   (United States)

Author keywords

Anti idiotype; Antibody dependent cellular cytotoxicity; Cancer; CD25; Complement dependent cytotoxicity; Cytotoxic T lymphocyte associated antigen 4; Monoclonal antibodies; Oregovomab; TGF

Indexed keywords

ABAGOVOMAB; ACA 125; ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; BEVACIZUMAB; BL 22 MONOCLONAL ANTIBODY; BMS 663513; CETUXIMAB; CP 675206; DACLIZUMAB; EPRATUZUMAB; GALIXIMAB; GANGLIOSIDE GD2; GD2 MONOCLONAL ANTIBODY; GEMTUZUMAB OZOGAMICIN; GENTUZUMAB OZOGAMICIN; HCD122 MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INOTUZUMAB OZOGAMICIN; IPILIMUMAB; MONOCLONAL ANTIBODY; OREGOVOMAB; RITUXIMAB; SGN 40 MONOCLONAL ANTIBODY; TGN 1412; TICILIMUMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN BINDING; ANTIGEN PRESENTATION; B CELL LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; METASTASIS; NONHODGKIN LYMPHOMA; RECEPTOR BLOCKING; REVIEW; TUMOR IMMUNITY;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; NEOPLASMS;

EID: 33847763956     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.3.331     Document Type: Review

References (92)

1. REICHERT JM, ROSENWEIG CJ, FADEN LD, DEWITZ MC: Monoclonal antibody successes in the clinic. Nat. Biotechnol. (2005) 23(9):1073-1078.
2. LONBERG N: Human antibodies from transgenic animals. Nat. Biotechnol. (2005) 23(9):1117-1125. • Comprehensive review of drugs in clinical testing, including sequences derived from human immunoglobulin transgenic mice.
3. CLARK M: Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today (2006) 21(8):397-402.
4. HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9(1):129-134.
5. LEFRANC M-P, LEFRANC G: The Immunoglobulin Facts Book. Academic Press, NY, USA (2001).
6. OSBORNE J, HARRISON P, BUTCHER R, EBSWORTH N, TAN K: Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma. Hybridoma (1999) 18:183-191
7. HAMERS-CASTERMAN C, ATARHOUCH T, MUYLDERMANS S et al.: Naturally occurring antibodies devoid of light chains. Nature (1993) (363):446-448.
8. NGUYEN VK, HAMERS R, WYNS L, MUYLDERMANS S: Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. Eur. Mol. Biol. Org. (2000) 19(5):921-930.
9. CARTER P: Bispecific human IgG by design. J. Immunol. Methods (2001) 248(1-2):7-15.
10. FRENCH MA: Serum IgG subclasses in normal adults. Monogr. Allergy (1986) 19:100.
11. PAUL WE: Fundamental Immunology. Lippincott Williams & Wilkins, Philadelphia, PA, USA (2003). • Comprehensive textbook outlining the fundamentals in immunology.
12. AALBERSE R: Serological aspects of IgG4 Abs: Prolonged immunization results in an IgG4-restricted response. J. Immunol. (1983) 130:722.
13. HAMMARSTROM L, SMITH C: IgG subclass changes in bacterial infections. Monogr. Allergy (1986) 19:122.
14. SKVARIL F: IgG subclass in viral infections. Monogr. Allergy (1986) 19:134.
15. DHODAPKAR KM, KRASOVSKY J, WILLIAMSON B, DHODAPKAR MV: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. (2002) 195(1):125-133.
16. + lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol. (2001) 101(3):276-283.
17. JERNE NK: Towards a network theory of the immune system. Ann. Immunol. (Paris) (1974) 125C:373-389. • Seminal work describing the idiotype network theory.
18. SCHULTES B, NICODEMUS C: Using antibodies in tumour immunotherapy. Expert Opin. Biol Ther. (2004) 4(8):1265-1284. • Extensive review of antibodies being studied as immunotherapeutics in cancer.
19. ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. (2003) 348(3):203-213.
20. CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949.
21. UMANA P, JEAN-MAIRET J, MOUDRY R, AMSTUTZ H, BAILEY J: Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody dependent cellular cytotoxic activity. Nat. Biotechnol. (1999) 17(2):176- 180.
22. RIECHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988) 332(6162):323-327.
23. ROBAK T: Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs (2005) 19(1):9-22.
24. TRIKHA M, YAN L, NAKADA MT: Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. (2002) 13(6):609-614.
25. VELDERS MP, LITVINOV SV, WARNAAR SO et al.: New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. (1994) 54(7):1753-1759.
26. MENDELSOHN J: Blockade of receptors for growth factors: An anticancer therapy. Clin. Cancer Res. (2000) 6(3):747-753.
27. GOLDBERG R, KIRKPATRICK P: Cetuximab. Nat. Rev. Drug Discov. (2005) 4(5):S10-S11.
28. TSIMBERIDOU AM, GILES FJ, ESTEY E et al.: The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br. J. Haematol. (2006) 132(4):398-409.
29. WHITE CA: Radioimmunotherapy in non-Hodgkin's lymphoma: Focus on 90Y-ibritumomab 305tiuxetan (Zevalin®). J. Exp. Ther. Oncol. (2004) 4(4):305-316.
30. WITZIG T: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc.) (2004) 40(2):111-119.
31. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83(2):435-445.
32. GRILLO-LOPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M: Rituximab: ongoing and future clinical development. Semin. Oncol. (2002) 2981(1):105-112.
33. CARTRON G, WATIER H, GOLAY J, SOLAL-CELIGNY P: From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 104(9):2635-2642.
34. 131I] tositumomab in the management of follicular lymphoma: an oncologist's view. Q. J. Nucl. Med. Mol. Imaging (2004) 48:305-316.
35. RAVETCH JV, CLYNES RA: Divergent roles for Fc receptors and complement in vivo. Annu. Rev Immunol. (1998) 16(1):421-432.
36. CARTER P, PRESTA L, GORMAN CM et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA (1992) 89(10):4285-4289.
37. EMENS LA: Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am. J. Ther. (2005) 12(3):243-253.
38. FINN RS, SLAMON DJ: Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother. Biol. Response Modif. (2003) 21:223-233.
39. CHEUNG NK, LAZARUS H, MIRALDI FD et al.: Ganglioside GD2 specific monoclonal antibody 3F8: a Phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. (1987) 5(9):1430-1440.
40. IRIE RF, MORTON DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl Acad. Sci. USA (1986) 83(22):8694-8698.
41. D2 antibody 14G2a in metastatic melanoma. Cancer Res. (1992) 52:4342-4347.
42. KREITMAN RJ, WILSON WH, BERGERON K et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345(4):241-247.
43. DIJOSEPH JF, DOUGHER MM, KALYANDRUG LB et al.: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res. (2006) 12(1):242-249.
44. UPPENKAMP M, ENGERT A, DIEHL V et al.: Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. Hematol. (2002) 81(1):26-32.
45. CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene. Blood (2002) 99(3):754-758.
46. LEFEBVRE M-L, KRAUSE SW, SALCEDO M, NARDIN A: Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. (2006) 29(4):388-397.
47. IMAI M, LANDEN C, OHTA R, CHEUNG NK, TOMLINSON S: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. (2005) 65(22):10562-10568.
48. RAGUPATHI G, LIU NX, MUSSELLI C et al.: Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. (2005) 174(9):5706-5712.
49. YIP Y, WARD R: Anti-ErbB-2 monoclonal antibodies and ErbB-2 directed vaccines. Cancer Immunol. Immunother. (2002) 50(11):569-587.
50. SALTZ LB, MEROPOL NJ, LOEHRER PJ SR et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(7):1201-1208.
51. SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182(1):18-32. • Description of T regulatory cells.
52. LOERCHER AE, NASH MA, KAVANAGH JJ, PLATSOUCAS CD, FREEDMAN RS: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. (1999) 163(11):6251-6260.
53. KRYCZEK I, ZOU L, RODRIGUEZ P et al.: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. (2006) 203(4):871-881.
54. FREY AB: Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. (2006) 116(10):2587-2590.
55. GALLINA G, DOLCETTI L, SERAFINI P et al.: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. (2006) 116(10):2777-2790.
56. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA (2003) 100(14):8372-8377.
57. VAN ELSAS A, HURWITZ AA, ALLISON JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. (1999) 190(3):355-366.
58. REUBEN J, LEE B, LI C et al.: Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer (2006) 106(11):2437-2444.
59. MAKER A, ATTIA P, ROSENBERG SA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. (2005) 175(11):7746-7754.
60. HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA (2003) 100(8):4712-4717.
61. KORMAN A, PEGGS K, ALLISON J: Checkpoint blockade in cancer immunotherapy. Adv. Immunol. (2006) 90:297-339. • Excellent review of counter-regulation in cancer immunotherapy.
62. PEGGS KS, QUEZADA SA, KORMAN AJ, ALLISON JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 18(2):206-213. • Comprehensive and up-to-date review of anti-CTLA-4 and its use in cancer therapy.
63. KOCAK E, LUTE K, CHANG X et al.: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. (2006) 66(14):7276-7284.
64. RIBOLDI E, MUSSO T, MORONI E et al.: Cutting Edge: Proangiogenic properties of alternatively activated dendritic cells. J. Immunol. (2005) 175(5):2788-2792.
65. GABRILOVICH DI, ISHIDA T, NADAF S, OHM JE, CARBONE DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. (1999) 5(10):2963-2970.
66. LAXMANAN S, ROBERTSON S, WANG E et al.: Vascular endothelial growth factor impairs the functional ability of dendritic cells through ID pathways. Biochem. Biophys. Res. Commun. (2005) 334(1):193-198.
67. LEONARD JP, COLEMAN M, KETAS JC et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma. Clin. Cancer Res. (2004) 10:5327-5334.
68. CZUCZMAN MS, THALL AD, WITZIG TE et al.: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. (2005) 23(19):4390-4398.
69. RAMIREZ-MONTAGUT T, CHOW A, HIRSCHHORN-CYMERMAN D et al.: Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. (2006) 176(11):6434-6442.
70. SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. (2006) 355(10):1018-1028.
71. KAUFMAN HL, WOLCHOK JD: Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J. Clin. Oncol. (2006) 24(15):2230-2232.
72. COHEN AD, DIAB A, PERALES MA et al.: Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity. Cancer Res. (2006) 66(9):4904-4912.
73. NAGAI H, HORIKAWA T, HARA I et al.: In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. (2004) 13(10):613-620.
74. FECCI PE, SWEENEY AE, GROSSI PM et al.: Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin. Cancer Res. (2006) 12(14):4294-4305.
75. NEEDHAM D, LEE J, BEILHARZ M: Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem. Biophys. Res. Commun. (2006) 343(3):684-691.
76. KO K, YAMAZAKI S, NAKAMURA K et al.: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. (2005) 202(7):885-891.
77. WEI S, KRYCZEK I, ZOU L et al.: Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. (2005) 65(12):5020-5026.
78. ZOU W, MACHELON V, CURIEL TJ et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. (2001) 7(12):1339-1346.
79. WOLF D, WOLF AM, RUMPOLD H et al.: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. (2005) 11(23):8326-8331.
80. BELLONE G, SMIRNE C, MAURI F et al.: Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimans: Implications for survival. Cancer Immunol. Immunother. (2006) 55(6):684-698.
81. DE BONO JS, RHA SY, STEPHENSON J et al.: Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. (2004) 15:1825-1833.
82. GORDON AN, SCHULTES BC, GALLION H et al.: CA125- and tumor specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol. (2004) 94:340-351.
83. BEREK JS, TAYLOR PT, GORDON A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22(17):3507-3516. • Results of Phase II/III trial with oregovomab in advanced ovarian cancer.
84. KANEKO Y, NIMMERJAHN F, RAVETCH JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 313(5787):670-673.
85. LINDEMAN J: Speculations on idiotypes of homebodies. Ann. Immunol. (Paris) (1973) 124:171-184. • Seminal work on the idiotype network.
86. REINARTZ S, KÖHLER S, SCHLEBUSCH H et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. (2004) 10:1580-1587.
87. PRITCHARD-JONES K, SPENDLOVE I, WILTON C et al.: Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer (2005) 92(8):1358-1365.
88. REECE D, FOON KA, BHATTACHARYA-CHATTERJEE M et al.: Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastic breast cancer. Clin. Breast Cancer (2003) 3(4):152-157.
89. DÍAZ A, ALFONSO M, ALONSO R et al.: Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol. (2003) 107(2):80-89.
90. SABBATINI P, DUPONT J, AGHAJANIAN C et al.: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. (2006) 12(18):5503-5510.
91. GIACCONE G, DEBRUYNE C, FELIP E et al.: Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer. J. Clin. Oncol. (2005) 23(28):6854-6864. • Description of the Phase III study results with the BEC2 anti-idiotypic antibody.
92. MURRAY JL, GILLOGLY M, KAWANO K et al.: Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patiens with melanoma. Cancer Res. (2004) 64(15):5481-5488.